Inhalation Sciences ships second fully commercialized DissolvIt module in one week

Following the historic shipment of its first commercialized DissolvIt® in vitro module, Inhalation Sciences has shipped a second module, to a returning pharmaceutical customer, within the same week. The customer placed the original purchase order for DissolvIt, worth 75,000 Euro (835,000 SEK), in December 2018. “We’ve long known DissolvIt was in demand” says CEO Manoush Masarrat, “this really proves it.”

The latest, second commercialized module has been shipped to a long-term ISAB pharma company in Southern Europe. After ten years in development DissolvIt has been tested in many contract research (CRO) projects, including ones with the present customer, delivering leading in vitro data that correlates closely to in vivo findings.

CEO Manoush Masarrat: “DissolvIt has been seen by many in the industry as the first tool that can seriously show In Vitro-In Vivo correlation (IVIVC). Precise, predictive, preclinical IVIVC data means drug developers can put credible strategies in place for formulation before crucial time and money has been spent in clinic—reducing risk and development costs and increasing precision and speed of development.”

DissolvIt is expected to create a new revenue stream for ISAB, through the sale of the tool’s disposable Dissolution Chambers. Every component in the final commercial release has been precision-engineered to eliminate risk of deviation. Key features such as the high-resolution optical microscopy camera, which shows particles dissolving in real-time on the simulated lung lining, have been fully optimized. DissolvIt’s easy-to-use software package automatically activates and measures every stage of the dissolution, again ensuring exacting precision and eliminating human interference.

“Like the first shipment, this one came out of a successful research collaboration” says Masarrat. “It underlines how the leading data DissolvIt generates impacts inhalation research so positively.”


DissolvIt key benefits and features:

  • Ranks substances according to solubility
  • Monitors absorption as well as dissolution
  • Identifies successful, effective Drug Candidates early on
  • Delivers exceptionally detailed data incl. Cmax and Tmax curves
  • Optical microscopy shows real-time dissolution of particles
  • Customizable, programmable Fraction Collector for flexible sampling


For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when being inhaled.


The information above was provided by Inhalation Sciences Sweden AB (publ) for publication on March 23, 2020.




Documents & Links